Reading PLSE? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track PLSE free→Reading PLSE? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track PLSE free→NASDAQHealth CareMedical Instruments & SuppliesSnapshot 2026-06-16
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
Recent financial performance is neutral, and management's recent track record has been unsteady, with frequent disruptive corporate changes. Earnings quality cannot be assessed as the company was unprofitable over the past year, and risk is elevated. The sector backdrop is a headwind, and compared with sector peers, it is below typical. The read is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 0 valuation methods, at three horizons. Current price $25.11. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
Not enough valuation methods to set a 12-month read yet.
TTM earnings are negative, so the read leans on sales- and cash-flow-based methods rather than P/E. This is a data condition, not a forward call.
Not enough peers to compare yet.
Self-history needs ~20 months of data.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 50% of the time over the next year (vs 57% for the rest of the cohort, n=3115).
Over the trailing year it converted 0.74x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity.
9 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated volatile grew net income 43% of the time over the next year (vs 57% for the rest of the cohort, n=600).
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
EPS estimate $-0.24 → $-0.28 (-18.8% / 30d). 0 raised, 1 cut, 2 covering analysts.
0 upgrades, 0 downgrades / 30d. 100% of analysts rate Buy.
1 PT revisions / 30d. Avg target 28.1% above current price.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$288.
How much price usually moves either way.
On a bad day, this stock has moved -$615.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $3,651.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
No material changes since the prior snapshot.
as of 2026-06-16
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
No named catalysts to watch right now. Check back after the next earnings report.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for PLSE yet.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
Results of Operations and Financial Condition. On May 4, 2026, Pulse Biosciences, Inc., a Delaware corporation (the “Company”), announced certain financial and operational results for the fiscal quarter ended March 31, 2026. A copy of the Company’s press release is attached hereto as Exhibit 99.1 and is incorporated herein by this reference. This information, as well as Exhibit 99.1, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Excha…
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
A side-by-side read on sector standing, valuation, and risk versus Health Care Supplies.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
PLSE Pulse Biosciences, Inc. | Below typical Show detailsSector percentile: 27 of 100 | — | elevated |
MDLN MEDLINE INC | — | full | moderate |
WST West Pharmaceutical Services | Above typical Show detailsSector percentile: 94 of 100 | expensive | moderate |
COO Cooper Companies (The) | Above typical Show detailsSector percentile: 75 of 100 | fair | moderate |
ALGN Align Technology | Above typical Show detailsSector percentile: 93 of 100 | fair | elevated |
Not investment advice. As of 2026-06-16.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-16.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Focus on developing products to increase revenue, particularly in the treatment of atrial fibrillation.
Newly stated in 2026-Q1. Revenue grew from $0 in 2025-Q2 to $401,000 in 2026-Q1, indicating initial progress in product development efforts. The CTO's leadership in developing treatments for atrial fibrillation is recognized, suggesting a strategic focus on this area. The trajectory shows early signs of delivering on revenue growth through product development.
“CTO awarded for continued leadership of product development efforts for atrial fibrillation.”
Focus on managing cash flow and reducing operating expenses to improve financial stability.
Newly stated in 2026-Q1. Cash from operating activities was -$14.6M in 2026-Q1, reflecting ongoing challenges in managing cash flow and operating expenses. The focus on cost management is critical given the negative cash flow, but progress is limited as expenses remain high.
“Cash from operating activities was negative, indicating a focus on managing expenses.”
Enhance the leadership team with strategic appointments to drive company growth.
Newly stated in 2026-Q1. The appointment of Liane R. Teplitsky as COO is a strategic move to strengthen the leadership team. This change aims to enhance the company's strategic direction and development capabilities, but the impact on financial performance is yet to be seen.
“Appointment of Liane R. Teplitsky as COO to lead strategy and development.”
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Chief Operating Officer Appointment Pulse Biosciences, Inc. (the “Company”) has appointed Liane R. Teplitsky as its Chief Operating Officer, effective as of April 8, 2026 (the “Start Date”). Ms. Teplitsky most recently served as Chief Executive Officer of Artedrone, where she led the strategy and development of an autonomous robotic technology for…
DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS. On March 23, 2026, the Compensation Committee of the Board of Directors of Pulse Biosciences, Inc. (the “Company”) awarded the Company’s Chief Technology Officer, Darrin R. Uecker, for his continued leadership of the Company’s product development efforts for the treatment of atrial fibrillation, a grant of restricted stock units representing 100,00…
DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS. On February 27, 2026, Kevin P. Danahy, the Chief Commercial Officer of Pulse Biosciences, Inc. (the “Company”) gave notice that he was resigning from the Company, effective immediately.
Results of Operations and Financial Condition. On February 19, 2026, Pulse Biosciences, Inc. (the “Company”) announced certain financial and operational results for the fiscal quarter and full year ended December 31, 2025. A copy of the Company’s press release is attached hereto as Exhibit 99.1 and is incorporated herein by this reference. This information, as well as Exhibit 99.1, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchang…